PLx Pharma Inc.
PLx Pharma Inc. (PLXP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PLXP · as of Jun 30, 2023
Ownership Breakdown
2
Institutional Holders
▼ 29 vs Q1
$161
Total Inst. Value
▼ $477,411 vs Q1
29.14M
Shares Outstanding
freeFloat 86.67%
61,483
13F Shares Held
▼ 3.61M vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PLXP largest shareholders · institutional ownership
Q2 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
STEWARD PARTNERS INVESTMENT ADVISORY, LLC pharmaceutical preparations | 43.9K | 15.34% | 15.34% | $123,000 | Aug 14, 2023 | — held |
BAADER BANK AKTIENGESELLSCHAFT pharmaceutical preparations | 17.6K | 6.16% | 6.16% | $38,000 | Aug 11, 2023 | NEW |
NORTHERN TRUST CORP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
VANGUARD GROUP INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
MORGAN STANLEY pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
GROUP ONE TRADING, L.P. pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 9, 2023 | EXIT |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 4, 2023 | EXIT |
FAYEZ SAROFIM & CO pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
STATE STREET CORP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2023 vs prior quarter
Q2 2023
0
Increased
+0 shares1
New Positions
first time holders0
Decreased
−0 shares30
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-29
1 new / 30 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PLXP insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
9
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Giordano Natasha Chief Executive Officer | Mar 15, 2022 | Purchase | 4,100 | $3.65 | $15.0K | 5.2K | Form 4 ↗ |
O'Connor Rita M Chief Financial Officer | Mar 15, 2022 | Purchase | 3,700 | $3.65 | $13.5K | 26.7K | Form 4 ↗ |
O'Connor Rita M Chief Financial Officer | Mar 15, 2022 | Purchase | 10,000 | $3.66 | $36.6K | 23.0K | Form 4 ↗ |
Valentino Michael J Executive Chairman | Feb 22, 2022 | Award | 80,000 | $4.99 | $399.2K | 80.0K | Form 4 ↗ |
O'Connor Rita M Chief Financial Officer | Feb 22, 2022 | Award | 110,000 | $4.99 | $548.9K | 110.0K | Form 4 ↗ |
HADDEN JOHN director | Feb 22, 2022 | Award | 20,000 | $4.99 | $99.8K | 20.0K | Form 4 ↗ |
Giordano Natasha Chief Executive Officer | Feb 22, 2022 | Award | 300,000 | $4.99 | $1.50M | 300.0K | Form 4 ↗ |
Casale Robert director | Feb 22, 2022 | Award | 20,000 | $4.99 | $99.8K | 20.0K | Form 4 ↗ |
CALHOUN KIRK K director | Feb 22, 2022 | Award | 20,000 | $4.99 | $99.8K | 20.0K | Form 4 ↗ |
Balkema Gary S. director | Feb 22, 2022 | Award | 20,000 | $4.99 | $99.8K | 20.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
PLx Pharma Inc. (PLXP) is primarily owned by institutional investors, who hold approximately 0.2% of total shares outstanding. Company insiders own approximately 13.33%, while retail and public investors account for the remaining 86.46%.
The largest institutional shareholder of PLx Pharma Inc. is STEWARD PARTNERS INVESTMENT ADVISORY, LLC, holding approximately 43,875 shares — equal to 15.34% of outstanding shares — as of June 30, 2023.
A total of 2 institutional investors currently hold PLXP stock, with a combined institutional value of approximately $161 as of the most recent 13F filing period.
Frequently asked questions
PLXP ownershipPLx Pharma Inc. (PLXP) is primarily owned by institutional investors, who hold approximately 0.2% of shares. The largest shareholder is STEWARD PARTNERS INVESTMENT ADVISORY, LLC with a 15.34% stake. Company insiders hold 13.33%. Data sourced from SEC Form 13F as of June 30, 2023.